ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In a bid to enhance its vaccines business, GlaxoSmithKline has acquired Okairos, a Swiss vaccine technology specialist, for about $325 million. Okairos is developing vaccines that use viral vectors to help stimulate immune responses. It has prophylactic products in development for diseases such as hepatitis C virus, malaria, tuberculosis, and Ebola. It is also developing therapeutic vaccines for cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X